• Traverse
    • Timmerman Traverse for Damon Runyon – Sierras 2026
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for Damon Runyon – Sierras 2026
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
8
Sep
2017

Allergan’s Tribal Patent Switcheroo; Cellectis, Alnylam See Trial Deaths; & Execs Defend Dreamers

/
Luke Timmerman
/
0
/
All
08 Sep 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Sep
2017

Replimune, Led by BioVex Vets, Snags $55M for New Oncolytic Viruses for Cancer

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
08 Sep 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Sep
2017

Gritstone Grabs $93M, Doubling Down on Personalized Neoantigen Cancer Vaccines

/
Luke Timmerman
/
2
/
All, Cancer
07 Sep 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Sep
2017

Novartis’ Historic CAR-T Approval, Gilead-Kite Megadeal, & FDA Crackdown on Stem Cell Hucksters

/
Luke Timmerman
/
0
/
All
01 Sep 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
31
Aug
2017

How Gilead Can Play to Win in CAR-T Over the Next Decade

/
Luke Timmerman
/
4
/
All, The Edge
31 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
28
Aug
2017

Getting to Precision Medicine – It’s Complicated

/
Leora Schiff
/
0
/
All, Cancer, Diagnostics, Drugs
28 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Aug
2017

Adamas Wins Parkinson’s Drug Approval, Genmab Soars, Amgen Defends PCSK9 Price

/
Luke Timmerman
/
0
/
All
25 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Aug
2017

Scott Gottlieb’s First 100 Days at the FDA: A Timeline

/
Luke Timmerman
/
0
/
All, Politics, The Edge
21 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Aug
2017

Industry Leadership Tests, Pfizer and AZ Win Cancer Drug Approvals, Unity Reloads

/
Luke Timmerman
/
0
/
All
18 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Aug
2017

We Can Follow Through On Our Own After Charlottesville

/
Stephen Graham
/
1
/
All, People, Politics
17 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Aug
2017

At What Price a Seat at the Table?

/
Steve Holtzman & Jeremy Levin
/
0
/
All, Politics
16 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Aug
2017

How Do You Manage Biotech Information to Think Widely and Deeply?

/
Luke Timmerman
/
1
/
All, The Edge
14 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Aug
2017

Grail Plucks Low-Hanging Fruit, eGenesis Creates PERV-Free Pigs, & Roivant Raises $1B

/
Luke Timmerman
/
0
/
All
11 Aug 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
31
Jul
2017

Whither Experts? A Review of The Death of Expertise and Some Thoughts for Biopharma

/
Kyle Serikawa
/
0
/
All, People, Politics
31 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Jul
2017

How Agios, Neurocrine Are Striving to Go Commercial, and Hold Onto Their Souls

/
Luke Timmerman
/
1
/
All, People
24 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Jul
2017

Vertex’s Grand Slam for CF, Puma Stretches on Price, Sarepta & BioMarin Bury the Hatchet

/
Luke Timmerman
/
0
/
All
21 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jul
2017

Family Offices: Quietly Putting Money to Work in Biotech Startups

/
Luke Timmerman
/
0
/
All
19 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Jul
2017

Novartis’ Big CAR-T Moment, Amicus Exits FDA Penalty Box, and Evelo’s Bold $50M Microbiome Play

/
Luke Timmerman
/
0
/
All
14 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Jul
2017

A One-Bug Drug For the Immune System? Evelo Gets $50M to Test Concept

/
Luke Timmerman
/
1
/
All, Cancer, Venture Capital
11 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Jul
2017

Allergan’s Social Contract, One Year Later: CEO Brent Saunders Reflects on the Expected and Unexpected

/
Luke Timmerman
/
1
/
All, The Edge
10 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 65 66 67 68 69 … 84 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2026, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder